Skip to main content
EJNMMI Research
Fig. 2 | EJNMMI Research

Fig. 2

From: Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study

Fig. 2

The difference in tumour-background ratio between [18F]FES and [18F]FDHT PET shown visually (a) and quantitatively (mean ± SD) for bone and lymph node lesions (b). The arrows in a show a bone lesion in the right os ilium visible on [18F]FES PET which is only subtly visible on [18F]FDHT PET. Note, there is physiological tracer uptake of [18F]FES in the liver, gallbladder, intestine, bladder and for [18F]FDHT also in the bloodpool

Back to article page